Technology Development Through Pooling ARV Drug Patents: A Vision from China [0.03%]
通过汇集ARV药物专利推动技术发展：来自中国的展望
Li Liu,Hongzhou Lu
Li Liu
Unaffordable prices still bar the end-users in China from accessing ARV drugs. Patent protection of ARV drugs has dramatically limited the availability of these lifesaving drugs to AIDS patients in China.The way Chinese government can go to...
Victor Rodriguez
Victor Rodriguez
Patent pools do not correct all problems associated with patent thickets. In this respect, patent pools might not stop the outsider problem from striking pools. Moreover, patent pools can be expensive to negotiate, can exclude patent holder...
Eric Noehrenberg
Eric Noehrenberg
Patent pools have been promoted as an innovative means of promoting the production of fixed-dose combination antiretroviral medicines (ARVs), which can be particularly appropriate for resource-poor settings. An important question, however, ...
Designing ARVs Patent Pool Up to Trade & Policy Evolutionary Dynamics [0.03%]
面向贸易与政策的进化动态的艾滋病 retroviral药物专利池设计研究
Daniele Dionisio,Vincenzo Racalbuto,Daniela Messeri
Daniele Dionisio
Patent pools for second and third-line Fixed Dose Combination (FDC) antiretroviral drugs (ARVs) should not be delayed as they are instrumental to urgent public health needs in the under-served markets.Nonetheless, multinational originator c...
Daniele Dionisio
Daniele Dionisio
Stavros Nicolaou
Stavros Nicolaou
AFFORDABILITY THROUGH REDUCED PRICING IS ONLY ONE PART OF ENHANCING ACCESS TO TREATMENT IN PUBLIC HEALTH EMERGENCIES: Supply Security and the guarantee of supply consistency is the other. To the extent that Patent Pooling is able to create ...
Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) - A Strategic Option for India [0.03%]
专利池与抗逆转录病毒药物的获取问题——印度的一种战略选择
Kanikaram Satyanarayana,Sadhana Srivastava
Kanikaram Satyanarayana
The current HIV/AIDS scenario in India is quite grim with an estimated 2.4 million people living with HIV/AIDS (PLHA) in 2008, just behind South Africa and Nigeria. The anti-retroviral drugs (ARVs) remain the main stay of global HIV/AIDS tr...
Michelle Childs
Michelle Childs
Recent WHO guidelines for antiretroviral therapy recommend switching to less toxic, but more expensive medicines for first-line and second-line ART, raising questions about the financial sustainability of many AIDS treatment programmes. At ...
Antiretroviral (ARV) Therapy in Resource Poor Countries: What do we Need in Real Life? [0.03%]
抗逆转录病毒在资源缺乏的国家：现实生活中需要什么？
Francesco Castelli,Virginio Pietra,Ismael Diallo et al.
Francesco Castelli et al.
Significant progresses have been made in the last 5 years towards the ultimate goal to provide universal access to care for all HIV/AIDS patients needing antiretroviral treatment in resource-poor countries. However, many barriers are still ...
Achieving a dream: meeting policy goals related to improving drug access [0.03%]
梦想成真：与改善药品可及性有关的政策目标实现情况
David Zakus,Jillian Clare Kohler,Venera Zakriova et al.
David Zakus et al.
International experts recognize that significant inequities exist in the accessibility of life-saving medicines among poor and vulnerable populations, especially in developing countries. This article highlights that drug access even for rel...